NCT03715933 2026-03-18
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Inhibrx Biosciences, Inc
Phase 1 Recruiting
Inhibrx Biosciences, Inc
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
Eli Lilly and Company
Eli Lilly and Company
Milton S. Hershey Medical Center
Dana-Farber Cancer Institute